Source: https://www.global-regulation.com/translation/italy/620192/reclassification-of-the-medicinal-product-for-human-use--protoxan--within-the-meaning-of-art.-8%252c-paragraph-10%252c-of-the-act-december-24%252c-1993%252c-%25.html
Timestamp: 2017-10-23 22:47:23
Document Index: 694817812

Matched Legal Cases: ['Art. 8', 'Art. 8', 'art. 8', 'art. 8', 'art. 1', 'art. 48', 'art. 12', 'Art. 1']

Machine Translation of "Reclassification Of The Medicinal Product For Human Use ' Protoxan ' Within The Meaning Of Art. 8, Paragraph 10, Of The ..." (Italy)
Reclassification Of The Medicinal Product For Human Use ' Protoxan ' Within The Meaning Of Art. 8, Paragraph 10, Of The Act December 24, 1993, # 537. (Resolution No. 122/2015).
Original Language Title: Riclassificazione del medicinale per uso umano «Protoxan» ai sensidell'art. 8, comma 10, della legge 24 dicembre 1993, n. 537.(Determina n. 122/2015).
Read the untranslated law here: http://www.gazzettaufficiale.it/atto/serie_generale/caricaArticoloDefault/originario?atto.dataPubblicazioneGazzetta=2015-02-27&atto.codiceRedazionale=15A01325&elenco30giorni=false&atto.tipoProvvedimento=DECRETO
The DIRECTOR-GENERAL having regard to articles 8 and 9 of legislative decree July 30, 1999, # 300; Visto l'art. September 30, 2003 48 of Decree-Law n. 269, converted into law November 24, 2003, n. 326, establishing the Italian medicines agency; Having regard to the Decree of the Minister of health in consultation with the Ministers for public administration and Economics and finance dated September 20, 2004, n. 245 laying down rules on the organisation and the functioning of the Italian Medicines Agency, pursuant to paragraph 13 of article. the aforementioned 48 as amended by order No. 53 of the Minister of health, in consultation with the Ministers for public administration and simplification and of economy and Finance of the March 29, 2012; Having regard to the Legislative Decree March 30, 2001, n. 165; Having regard to act July 15, 2002, # 145; Having regard to the Decree of the Minister of health of November 8, 2011, recorded by the Central Office of the budget to the register "visas", sheet # 1282, dated November 14, 2011, with which he was appointed Director General of the Italian Medicines Agency. Luca Pani, as from November 16, 2011; Having regard to act December 24, 1993, no. 537 concerning "public finance corrective" with particular reference to art. 8; Visto l'art. 1, paragraph 40, December 23, 1996, law n. 662 on "rationalization measures of public finance", which identifies the margins of distribution for pharmaceutical companies, wholesalers and pharmacists; Visto l'art. 48, paragraph 33, November 24, 2003, law No. 326, which has negotiating the price for products reimbursed by authorisation holders between agency and S. N.; Having regard to the Legislative Decree of April 24, 2006, n. 219, published in the Gazzetta Ufficiale della Repubblica italiana n. 142 of June 21, 2006 on the introduction of Directive 2001/83/EC (and subsequent amending directives) on the Community code relating to medicinal products for human use and Directive 2003/94/EC; Having regard to the 1 February 2001 CIPE; View the determination October 29, 2004 "Notes AIFA 2004 (Revision Notes CUF)", published in the ordinary supplement to the official journal # 259 of November 4, 2004 as amended; View AIFA'S determination of July 3, 2006 published in the official journal-General series n. 156 of July 7, 2006; View AIFA determination of September 27, 2006 published in the official journal-General series No 227 of September 29, 2006 concerning "maneuver for Government subsidized and non-subsidized pharmaceutical expenditure"; Visto l'art. 12, paragraph 5, of Decree-Law No 158 September 13, 2012, converted, with amendments, by law November 8, 2012, # 189; Given the decree by which the company Rivoira Pharma S.r.l. It was cleared for placing the medicinal product on PROTOXAN; Having regard to the application with which the firm Rivoira Pharma S.r.l. He requested the reclassification of the packs with # 042646012 to 042646099 from MA; Having regard to the opinion of the scientific and Technical Advisory Committee at its meeting of December 10, 2014;
Causes: Art. 1 Classification for the purposes of new listings is the medicine Protoxan in the packages below is classified as follows: 50%/50% gas packaging: "medicine" 5 lt tank with steel valve PRV-042646012 (10) 18PGHW (based on 32) new listings ' class: 50%/50% C packaging: "medicinal" 5 cylinder gas lt steel with integrated regulator-042646024 (10) 18PGJ8 (based on 32) new listings ' class : 50%/50% C packaging: "medicinal" 5 cylinder gas lt aluminum with integrated regulator-042646036 (10) 18PGJN (based on 32) new listings ' class: 50% 50%/C gas packaging: "medicine" 5 cylinder aluminum valve PRV-042646048 lt (based on 10) 18PGK0 (based on 32) new listings ' class: 50%/50% C packaging: "medicinal" gas canister from 10 lt aluminum valve PRV-042646051 (10) 183GK3 (based on 32) new listings ' class : 50%/50% C packaging: "medicinal" gas canister from 10 lt aluminum with integrated regulator-042646063 (10) 183GKH (based on 32) new listings ' class: 50%/50% C packaging: "medicinal" gas canister from 10 lt steel with valve PRV-042646075 (10) 183GKV (based on 32) new listings ' class: 50%/50% C packaging: "medicinal" gas canister from 10 lt steel with integrated regulator-042646087 (10) 183GL7 (based on 32) new listings ' class : C packaging: "50%/50% gas medicine" 50 lt cylinder PRV valve steel-042646099 (10) 183GLM (based on 32) new listings ' class: C